Neutrophil gelatinase-associated lipocalin and acute kidney injury

Neutrophil gelatinase-associated lipocalin (NGAL) is a new member of lipid protein family, which is a kind of stable polypeptide firstly separated from neutrophils. As a new biomarker of acute kidney injury (AKI) for early clinical diagnosis. NGAL is less easily affected by factors such as the body itself, drugs or aspects outside kidney. The high levels of NGAL in the blood and urine can both predict AKI. Dynamic monitoring NGAL can assess the validity of clinical therapy and give reference to treatment of AKI. Key words: Neutrophil gelatinase-associated lipocalin; Acute kidney injury; Biomarker; Early diagnosis